Comparative Analysis of Ki-67 Protein as a Proliferative Expression Index in Cutaneous Basal and Squamous Cell Carcinoma in Federal Medical Centre Umuahia, Nigeria

Background: Evaluating the tumor proliferative index helps predict clinical behavior and provides prognostic insights for cutaneous basal cell carcinoma (cBCC) and squamous cell carcinoma (cSCC). Objective: This study aimed to identify differences in the proliferative indices among variants of cBCC and cSCC diagnosed at a tertiary healthcare center. Method: Skin biopsies histologically diagnosed as cBCC and cSCC between 2012 and 2018 at the Federal Medical Centre (FMC) Umuahia, Abia State, Nigeria, were analyzed. Archival formalin-fixed, paraffin-embedded (FFPE) tissue blocks were retrieved along with clinical data, and were prepared on charged microscope slides and the immunohistochemical staining was carried out. The primary antibody used in this study was clone BioCare CRM325C (RM) and adenotonsillar tissue blocks/slides served as positive controls. Ki-67 immunohistochemistry was performed on fresh 4µm sections of the tumor specimens. Results: The application of Ki-67 immunoperoxidase on both BCC and SCC cohort, yielded an intense observable brownish nuclear stain in areas of dense proliferating tumour cells on both cutaneous tumours. The average Ki-67 index for all cSCC cases was 24.7%, with a range of 2.3% - 80%, while the mean for cBCC was 15.8%, ranging from 1.2% - 45.6%. Variants with high proliferative indices were observed in 11.9% of cBCC cases and 29.1% of cSCC cases. Among the low proliferative index category, cSCC accounted for 5.4%, while cBCC represented 14.3%. For mild proliferative indices, cSCC cases made up 7.3% and cBCC, 11.9%. The majority of cases showed moderate proliferative indices, with 61.9% for cBCC and 58.2% for cSCC. Overall, there was a significant difference in proliferative indices between cSCC, cBCC, and their variants. Conclusion: The study found a significantly higher rate of cell proliferation, measured by Ki-67 immunostaining, in cSCC and its variants compared to cBCC. However, certain variants of cBCC also exhibited high Ki-67 expression, indicating they can be as aggressive as some cSCC variants.

Influence of norcantharidin on proliferation,proliferation-related gene proteins prolifera-ting cell nuclear antigen and Ki-67 of human gallbladder carcinoma GBC-SD cells

BACKGROUND: Gallbladder carcinoma is a highly lethal and aggressive disease with early metastasis, strong invasion and poor prognosis. Most patients with this disease are at the advanced and un-resectable stage and should be consi- dered for palliative treatment such as chemotherapy and ra- diotherapy. Unfortunately, reports of chemotherapy and radiotherapy for gallbladder carcinoma are disappointing. We investigated the influence of norcantharidin (NCTD) on proliferation, proliferation-related gene proteins PCNA and Ki-67 of human gallbladder carcinoma GBC-SD cells in vitro. METHODS: GBC-SD cell lines of human gallbladder carci- noma were cultured by the cell culture technique. The ex- periment was divided into NCTD group and control group. The tetrazolium-based colorimetric assay was used to evaluate cell growth. The streptavidin-biotin complex method was used to determine the expressions of prolifera- tion-related gene proteins PCNA and Ki-67 of human gall- bladder carcinoma GBC-SD cells. RESULTS: NCTD inhibited the growth and proliferation of GBC-SD cells from 10 mg/L or after 6 hours in a dose- and time-dependent manner, with the IC50 value of 56.18 μg/ ml at 48 hours. After treatment with NCTD, the expression of PCNA (0.932 ±0.031 vs. 0.318 ±0.023, P<0.001) and Ki-67 (0.964 ±0.092 vs. 0.297 ±0.018, P<0.001) proteins were decreased significantly. CONCLUSION: NCTD inhibits the proliferation of human gallbladder carcinoma GBC-SD cells in vitro and the expres- sion of their proliferation-related gene proteins PCNA and Ki-67.

P53、P16及Ki-67与早期食管癌患者ESD术后复发的关系分析

目的 分析研究抑制蛋白基因P53(P53)、抑制蛋白基因P16(P16)及细胞增殖核抗原Ki-67(Ki-67)与早期食管癌患者内镜黏膜下剥离术(ESD)术后复发的关系。方法 选取2019年1月至2023年1月三门峡市中心医院收治80例的早期食管癌患者作为研究对象,均进行ESD治疗。比较所有患者癌组织与癌旁组织(距肿瘤边缘>3 cm,镜下未见肿瘤组织或不典型增生组织)P53、P16、Ki-67蛋白表达。ESD术后对患者随访1年,根据有无术后复发食管癌,将患者分为复发组(n=20)与无复发组(n=60)。比较两组癌组织P53、P16、Ki-67蛋白表达。采用多因素Logistic回归分析早期食管癌患者ESD术后复发的影响因素,并绘制ROC曲线分析P53、P16、Ki-67蛋白表达与早期食管癌患者ESD术后复发。结果 与癌旁组织相比,癌组织P53、Ki-67蛋白表达升高,P16蛋白表达降低(t=9.276、13.987、10.595,均P<0.05);复发组的癌组织P53、Ki-67蛋白表达均高于无复发组,P16蛋白表达低于无复发组(t=5.086、4.648、5.139,均P<0.05);多因素Logistic回归分析显示,肿瘤低分化(OR=1.870)、肿瘤浸润侵犯黏膜下层(OR=1.808)、有淋巴结转移(OR=2.089)、P53蛋白高表达(OR=2.046)、P16蛋白低表达(OR=1.988)及Ki-67蛋白高表达(OR=1.761)均是早期食管癌患者ESD术后复发的独立危险因素(P<0.05);ROC曲线分析显示,P53、P16、Ki-67蛋白表达及联合检测的曲线下面积(AUC)分别为0.803、0.828、0.834、0.942,联合检测优于单一检测(P<0.05)。结论 P53、P16及Ki-67蛋白与早期食管癌患者ESD术后复发情况相关,可以作为辅助预测的相关诊断指标。

Effects of Peptide Nucleic Acids against Ki-67 Gene on the Proliferation and Apoptosis of Human Renal Carcinoma Cell Line

To investigate the effects of anti-sense peptide nucleic acids （PNAs） targeting Ki-67 gene on modulation of the proliferation and apoptosis of human renal carcinoma cell lines, human renal carcinoma cell line 786-0 cells were treated with anti-sense PNAs at different concentrations （1.0 μmol/L, 2.0 μmol/L, 10.0 μmol/L）. The Ki-67 expression of 786-0 cells was detected by immunohistochemical technique and Western blot method respectively. The proliferation of 786-0 cells was studied by cell growth curves and ^3H-thymidine incorporation. The apoptosis of 786-0 cells was detected by TUNEL assay. The control groups were treated with anti-sense oligonucleotide （ASODNs） targeting Ki-67 gene. Our results showed that the Ki-67 expression of 786-0 cells treated with anti-sense PNAs （16.9±0.7） was significantly inhibited as compared with that of the control groups （28.6±0.4） （P〈0.01）. The Ki-67 protein rate of 786-0 cells treated with anti-sense PNAs （42.1 ±2.2） was significantly reduced when compared with that of the control groups （83.6± 1.4） （P〈0.01）. Proliferation of 786-0 cells treated with anti-sense PNAs （20.7 ± 1.5） was significantly inhibited as compared with that of the control groups （58.6± 1.4） （P〈0.01）. The apoptosis rate of 786-0 cells treated with anti-sense PNAs （28.7 ± 2.3） was significantly increased higher compared with that of the control groups （13.8 ±1.0） （P〈0.01）. From these finds we are led to conclude that anti-sense PNAs targeting Ki-67 gene have stronger effects on the inhibition of the proliferation and induction of apoptosis of human renal carcinoma cells than ASODNs targeting Ki-67 gene. The strategies using anti-sense PNAs targeting Ki-67 gene may be a promising approach for the treatment of renal cell carcinoma.

子宫内膜癌患者组织中PD-L1、Ki-67表达及意义

目的研究子宫内膜癌(EC)患者组织中程序性细胞死亡配体-1(PD-L1)、增殖细胞核抗原-67(Ki-67)的表达情况及临床意义。方法收集2022年1月至2023年8月医院行手术治疗的110例EC患者癌组织,根据TNM分期为A组(Ⅰ期,n=25)、B组(Ⅱ期,n=41)、C组(Ⅲ期,n=31)、D组(Ⅳ期,n=13)。采用免疫组织化学法检测4组癌组织中PD-L1、Ki-67表达情况及临床意义。结果4组的基线资料比较,差异无统计学意义(P>0.05);D组的CA125、CA199水平,PD-L1、Ki-67阳性表达率均高于A、B、C组,且组间两两比较,差异均有统计学意义(P<0.05);经Kendall’s tau-b相关性分析结果显示,EC患者组织中PD-L1、Ki-67表达、CA125、CA199水平与临床分期之间呈正相关(R值分别为0.314、0.354、0.306、0.392,P<0.05);经有序Logistic回归分析结果显示,以Ⅰ期为参照,PD-L1、Ki-67阳性率降低时,EC患者临床分期高的可能性分别为0.145倍、0.320倍(P<0.05),血清CA125、CA199水平与EC患者临床分期有关(OR>0.05,P<0.05)。结论EC患者组织中PD-L1、Ki-67的阳性表达率存在异常变化,且与患者临床分期存在一定的关系。

Effect of norcantharidin on proliferation and invasion of human gallbladder carcinoma GBC-SD cells

AIM: To investigate the effect of norcantharidin on proliferation and invasion of human gallbladder carcinoma GBC-SD cells in vitro and its anticancer mechanism. METHODS: Human gallbladder carcinoma GBC-SD cells were cultured by cell culture technique. The growth and the invasiveness of GBC-SD cells in vitro were evaluated by the tetrazolium-based colorimetric assay and by the Matrigel experiment and the crossing-river test. Expression of PCNA, Ki-67, MMP2 and TIMP2 proteins of GBC-SD cells was determined by streptavidin-biotin complex method. RESULTS: In vitro norcantharidin inhibited the growth and proliferation of GBC-SD cells in a dose- and time-dependent manner, with the IC50 value of 56.18 μ/mL at 48 h. Norcantharidin began to inhibit the invasion of GBC-SD cells at the concentration of 5 μg/mL, and the invasive action of GBC-SD cells was inhibited completely and their crossing-river time was prolonged significantly at 40 μg/mL. After treatment with norcantharidin, the expression of PCNA, Ki-67, and MMP2 was significantly decreased. With the increase in TIMP2 expression, the MMP2 to TIMP2 ratio was decreased significantly (P<0.05). CONCLUSION: Norcantharidin inhibits the proliferation and growth of human gallbladder carcinoma cells in vitro at relatively low concentrations by inhibiting PCNA and Ki-67 expression. Its anti-invasive activity may be the result of decrease in MMP2 to TIMP2 ratio and reduced cell motility.

Effect of preoperative transcatheter arterial chemoembolization on proliferation of hepatocellular carcinoma cells

AIM： To evaluate the effect of preoperative transcatheter arterial chemoembolization （TACE） on proliferation of hepatocellular carcinoma （HCC） cells. METHODS： A total of 136 patients with HCC underwent liver resection. Of 136 patients, 79 patients received 1 to 5 courses of TACE prior to liver resection （TACE group）, who were further subdivided into four groups： Group A （n = 11） who received i to 4 courses of chemotherapy alone; Group B （n = 33） who received i to 5 courses of chemotherapy combined with iodized oil; Group C （n = 23） who received i to 3 courses of chemotherapy combined with iodized oil and gelatin sponge; and Group D （n = 12） who received 1 to 3 courses of chemotherapy combined with iodized oil, ethanol and gelatin sponge. The other 57 patients only received liver resection （non- TACE group）. The expressions of Ki-67 and proliferating cell nuclear antigen （PCNA） protein were detected in the liver cancer tissues by immunohistochemical method. RESULTS： The Ki-67 protein expression was significantly lower in Groups C and D as compared with non-TACE group （31.35% ± 10.85% vs 44.43% ± 20.70%, 30.93% ± 18.10% vs 44.43% ± 20.70%, respectively, P 〈 0.05）. The PCNA protein expression was significantly lower in Groups C and D as compared with non-TACE group （49.61% ± 15.11% vs 62.92% ± 17.21%, 41.16% ± 11.83% vs 62.92% ± 17.21%, respectively, P 〈 0.05）. The Ki-67 protein expression was significantly higher in Group A as compared with non-TACE group （55.44% ± 13.72% vs 44.43% ± 20.70%, P 〈 0.05）. The PCNA protein expression was significantly higher in Groups A and B as compared with non-TACE group （72.22% ± 8.71% vs 62.92% ± 17.21%, 69.91% ± 13.38% vs 62.92% ± 17.21%, respectively, P 〈0.05）. CONCLUSION： Preoperative multi-material TACE suppresses the proliferation of HCC cells, while a single material embolization and chemotherapy alone enhance the proliferation of HCC cells.

超声造影定量参数对Luminal型乳腺癌诊断价值及其与雄激素受体及Ki-67的相关性研究

目的:探讨超声造影定量参数在Luminal型乳腺癌诊断中的价值,分析Luminal型乳腺癌患者超声造影定量参数与其雄激素受体(AR)及肿瘤增殖细胞相关抗原Ki-67的相关性。方法:选取医院收治的90例Luminal型乳腺癌患者,并根据病理及免疫组化检测结果将其分为LuminalA型组(32例)和LuminalB型组(58例),比较两组患者超声造影表现差异及定量参数,同时比较定量参数与Ki-67及AR表达水平的相关性。结果:两组患者的超声造影增强强度、灌注缺损、增强边界及穿入血流表现比较,差异均有统计学意义(x^(2)=5.204,x^(2)=11.880,x^(2)=6.556,x^(2)=7.249;P<0.05)。LuminalB型组患者与LuminalA型组相比,病灶区域血流灌注的峰值强度(PI)上升,达峰时间(TTP)及平均渡越时间(TOF)下降,差异均有统计学意义(t=8.084,t=8.639,t=7.945;P<0.05)。LuminalA型组患者Ki-67及AR阳性检出率低于LuminalB型组,差异有统计学意义(x^(2)=4.224,x^(2)=4.262;P<0.05)。90例Luminal型乳腺癌患者PI与Ki-67和AR表达水平均呈正相关(r=0.159,r=0.657;P<0.05);TTP、TOF与Ki-67和AR表达水平均呈负相关(r=-0.537,r=-0.407;r=-0.503,r=-0.023;P<0.05)。结论:超声造影定量参数对Luminal型乳腺癌的临床诊断价值较高,并与AR、Ki-67具有一定的相关性,可用于对Luminal型乳腺癌状况变化的诊断评估。

Molecular biomarkers of cell proliferation in ameloblastomas

Cell proliferation is a vital biological process that is important for all living organisms because of its role in growth and the maintenance of tissue homeostasis.The control of this important process differs greatly among benign and malignant neoplasms,and the evaluation of cell proliferation in neoplasms has become a common tool used by pathologists to provide useful information pertaining to diagnosis,clinical behavior,and treatment.The usefulness of information regarding cell proliferation has led to numerous studies on the value of these methods for diagnosing different types of tumors and for clinical decision making.Ameloblastomas are no exception.This review discusses the use of several classical molecular proliferation markers,including Ki-67,proliferating cell nuclear antigen,cyclin D1 and DNA topoisomeraseⅡalpha,to characterize ameloblastomas and proposes the use of new proliferation markers used previously to characterize other neoplasms.The use of these biomark-ers offers valuable opportunities to evaluate the biological behavior of this type of odontogenic tumor.

Cyclin D1、Ki-67、CK19联合评估甲状腺乳头状癌的效能及与颈部淋巴结转移的相关性分析

目的:探讨细胞周期蛋白D1(Cyclin D1)、细胞增殖抗原-67(Ki-67)、细胞角蛋白19(CK19)联合评估甲状腺乳头状癌(PTC)的效能,分析三者与颈部淋巴结转移的相关性。方法:选取我院2017年9月至2021年9月收治的91例PTC患者为PTC组,取同期收治的结节性甲状腺肿患者52例为对照组。两组均通过手术获取病变组织,检测Cyclin D1、Ki-67、CK19表达情况,分析三者对PTC的诊断价值。根据PTC患者有无颈部淋巴结转移,分成转移组、非转移组,比较两组病理组织中Cyclin D1、Ki-67、CK19表达情况,经多元Logistic回归模型分析三者与PTC患者颈部淋巴结转移的关系。结果:PTC组Cyclin D1、CK19阳性表达率分别为83.52%、85.71%,高于对照组的17.31%、17.31%(P<0.05);PTC组Ki-67>1%占比为93.41%,高于对照组的13.46%(P<0.05)。Cyclin D1、Ki-67、CK19单独诊断PTC的敏感度分别为83.52%、93.41%、85.71%,特异度分别为82.69%、86.54%、82.69%,三者联合诊断的敏感度、特异度分别为91.21%、96.15%。转移组的Cyclin D1、CK19阳性表达率分别为97.06%、97.06%,高于非转移组的75.44%、78.95%(P<0.05)。多元Logistic回归分析显示,Cyclin D1阳性表达会增加PTC患者颈部淋巴结转移风险(OR:3.446,95%CI:1.041~11.407,P<0.05)。结论:PTC患者的Cyclin D1、Ki-67、CK19阳性表达率较高,三者联合对PTC有较好的诊断效能,其中Cyclin D1阳性表达与颈部淋巴结转移相关。

Melanin Uptake Reduces Cell Proliferation of Human Epidermal Keratinocytes

Melanin, synthesized by melanocyte, is transferred to neighboring keratinocyte and finally accumulates in perinuclear site. Except functioning as an internal sunscreen to protect from UV damage, the potential effect of melanin on modulating the bioactivity of keratinocyte has not yet been fully investigated. In this study, we added melanin directly to the culture of human epidermal keratinocytes and the uptake of melanin was found to be dose- and time-dependent as determined by spectrophotometric method. The uptaken melanin accumulated perinuclearly in keratinocytes that is similar to the pattern observed in human solar lentigo tissue by microscopic examination. Pretreatment of keratinocytes with either niacinamide or trypsin inhibitor reduced the uptake of melanin dose-dependently, indicating a PAR-2-dependent pathway involved. Melanin uptake by keratinocytes inhibited cell proliferation as demonstrated both by the decrease of cell number and nuclear Ki-67 expression. Inhibited Ki-67 expression in melanin-containing keratinocyte was also found in human lentigo tissue. The cell cycle arrested at G1 phase in melanin-uptaken keratinocytes was confirmed by flow cytometric method. The protein expressions of cyclin-dependent kinase 1 (CDK1), CDK2, cyclin E, cyclin A and cyclin B were significantly reduced by melanin treatment. Microarray analysis, RT/real-time PCR and western blot demonstrated the inhibited expression of DKK1, a protein known to reduce skin pigmentation, in melanin-uptaken keratinocytes. Together, the direct incubation of keratinocyte with melanin might serve as a useful model to study the potential mechanisms involved in melanin uptake and pigmentation process.

子宫内膜癌组织中Ki-67、p16蛋白的表达及其对手术治疗预后的评估价值

目的 观察子宫内膜癌(EC)组织中增殖细胞核抗原-67(Ki-67)、抑癌基因p16蛋白表达,分析EC组织中Ki-67、p16蛋白表达对手术治疗预后的评估价值。方法 选择137例实施手术治疗的EC患者作为研究对象,收集患者的EC组织,检测Ki-67、p16在EC组织中的表达,随访2年,评估患者预后(复发、转移发生)情况,比较不同预后EC患者基线资料、实验室指标,重点分析EC患者组织中Ki-67、p16蛋白表达对手术治疗预后的预测。结果 随访2年,137例EC患者中17例复发,4例转移,预后不良发生率为15.33%(21/137)。经Logistic回归分析结果显示,国际妇产科协会(FIGO)分期高、Ki-67表达高可能是EC患者淋巴结转移的风险因子(OR>1,P<0.05),p16表达高可能是EC患者手术治疗预后的保护因子(OR<1,P<0.05)。绘制ROC曲线图,结果显示,Ki-67、p16蛋白表达预测EC患者手术治疗预后不良的AUC分别为0.833、0.827,均有一定预测价值;绘制决策曲线结果显示,在阈值0.2~1.0范围内,联合子宫内膜癌患者组织中Ki-67、p16蛋白表达预测EC患者手术治疗预后不良的净受益率优于单独某一指标,且在高风险阈值0.0~1.0内的净受益率始终大于0,始终有临床意义,净受益率最大值为0.153。结论 子宫内膜癌组织中Ki-67、p16蛋白表达与手术治疗预后有关,用于预测预后不良具有一定的价值,且联合预测获得的净受益率更高。

p53、Ki-67、PCNA的表达与食管鳞癌放疗近期疗效及预后的关系

目的:探讨食管鳞癌组织中p53、Ki-67及增殖细胞核抗原(PCNA)的表达与食管癌患者放疗近期疗效及预后的关系。方法:收集接受放疗的食管癌患者83例,采用免疫组化方法检测活检癌组织中p53、Ki-67及PCNA的表达,并分析其与临床病理特征、放疗疗效和预后的关系。结果:p53、Ki-67及PCNA在食管鳞癌中高表达率分别为57.8%、72.3%、67.5%。p53、Ki-67及PCNA表达与性别、年龄、侵犯部位、肿瘤长度等各临床病理因素无关(P>0.05),p53与肿瘤分化程度、临床分期、淋巴结转移、放疗近期疗效明显相关(P<0.05),Ki-67与肿瘤分化程度、淋巴结转移、放疗近期疗效明显相关(P<0.05),PCNA与临床分期、淋巴结转移、放疗近期疗效明显相关(P<0.05)。p53低、高表达组食管癌患者3年总生存率分别为57.14%、27.08%。结论:p53、Ki-67及PCNA可作为评价食管癌恶性程度、放射敏感性的生物学指标,p53可作为评价食管癌预后的有效指标。

LRIG3基因沉默对神经胶质瘤细胞系GL15增殖及PCNA和Ki-67表达的影响

背景与目的:富含亮氨酸重复序列免疫球蛋白样蛋白3(leucine-rich repeats and immunoglobin-like domains3,LRIG3)是LRIG基因家族成员之一,在多种肿瘤中均有表达下调,但其作用尚不明了。本研究旨在探讨RNA干扰沉默LRIG3基因表达对神经胶质瘤细胞系GL15增殖及增殖细胞核抗原(proliferating cell nuclear antigen,PCNA)和Ki-67表达的影响及其机制。方法:用携带U6启动子和LRIG3特异性短发夹RNA(short hairpin RNA,shRNA)序列的质粒载体pGenesil2-LRIG3-shRNA1、pGenesil2-LRIG3-shRNA2及含非特异性shRNA编码序列的对照质粒pGenesil2-negative shRNA(neg)转染胶质瘤细胞系GL15,G418筛选出稳定株,逆转录聚合酶链反应(RT-PCR)和Western blot法检测LRIG3表达的改变,应用噻唑蓝(MTT)法检测稳定转染后对GL15细胞增殖的影响,应用免疫组化SABC法检测对照组和实验组GL15细胞中PCNA和Ki-67的表达。结果:shRNA1及shRNA2组细胞LRIG3 mRNA水平与对照组相比分别下降了52.4%和63.8%,LRIG3蛋白水平分别下降了50.9%和67.4%。MTT结果显示实验组细胞增殖率高于对照组。对照组细胞PCNA阳性率为(35.40±5.69)%,shRNA1及shRNA2组细胞PCNA阳性率分别为(72.13±5.64)%和(81.93±5.23)%,差异均有统计学意义(P<0.01)。Ki-67阳性率在对照组细胞为(49.73±5.73)%,shRNA1及shRNA2组细胞分别为(82.27±5.50)%和(88.67±3.52)%,差异均有统计学意义(P<0.01)。Ki-67表达与PCNA表达呈正相关(r=0.932,P<0.001)。结论:下调LRIG3基因表达可促进胶质瘤细胞的增殖。

脑肿瘤细胞PCNA和Ki-67表达的对比观察

观察45例（4组）原发性脑肿瘤的免疫组化研究发现：增殖细胞核抗原（PCNA）和Ki67抗原（Ki－67）阳性率均为100％，两种阳性细胞密度均随肿瘤恶性程度增加而升高，并与肿瘤体积呈正相关，两种阳性细胞密度间也呈正相关，各肿瘤组PCNA阳性细胞密度均高于同组Ki－67阳性细胞密度。提示PCNA和Ki－67表达水平均能较客观地反应脑肿瘤的增殖速度和恶性程度。PCNA能用于石蜡切片是检测增殖期细胞更实用的标记物。

骨肉瘤P21^(WAF1)蛋白、PCNA与Ki-67的表达及其意义

目的 :研究骨肉瘤组织中P2 1WAF1 蛋白、增殖细胞核抗原 (PCNA)、Ki 6 7蛋白的表达 ,及其与骨肉瘤的发生、发展之间的关系及对预后的影响。方法 :用免疫组化LSAB法检测P2 1WAF1 蛋白、增殖细胞核抗原 (PCNA)、Ki 6 7蛋白在骨肉瘤中的表达。结果 :45例骨肉瘤中 ,P2 1WAF1 有 8例阳性表达 ,阳性率为 17.77% ;PCNA均有表达 ,阳性率为 10 0 % ;Ki 6 7有 2 7例阳性表达 ,阳性率为 6 0 %。结论 :P2 1WAF1 的低表达、PCNA、Ki 6 7的高表达 ,从一个侧面反映了骨肉瘤的恶性程度较高 ,检测P2 1WAF1 蛋白、增殖细胞核抗原 (PCNA)、Ki 6 7蛋白等多个指标可较全面反映骨肉瘤的恶性程度的高低及患者的预后情况。

胃癌中SPARC、TGFβ1和Ki-67的表达及意义

目的探讨胃癌组织中SPARC和TGFβ1的表达及其与胃癌细胞增殖的关系。方法用免疫组织化学方法检测80例胃癌组织和30例癌旁正常组织中SPARC、TGFβ1和Ki-67的表达。结果 (1)SPARC在胃癌中的阳性率高于正常胃黏膜(P=0.001)并主要表达于胃癌间质纤维母细胞的胞质,且与胃癌的分化程度、临床分期、Lauren分型及淋巴结转移相关有显著性(P<0.05);(2)胃癌中TGFβ1的阳性率和Ki-67标记指数均高于正常胃黏膜(P<0.001),且均与浸润深度、临床分期和淋巴结转移相关(P<0.05);(3)随着胃癌组织中SPARC的减少及TGFβ1的增多,Ki-67标记指数逐渐增大,且差异有显著性(P<0.05)。结论胃癌组织中SPARC抑制癌细胞的生长,而TGFβ1则促进癌细胞的生长,它们在胃癌的发生、发展中起着重要的作用。

肝细胞癌和肝硬化组织中增殖细胞核抗原及Ki-67抗原的表达及意义

为探讨肝细胞癌 (HCC)和肝硬化组织中增殖细胞核抗原 (PCNA)及 Ki- 67抗原的表达及意义 ,采用免疫组织化学技术检测 PCNA和 Ki- 67抗原在 HCC和肝硬化组织中的标记指数 (L I)。结果显示 , 、 、 级 HCC的 PCNA L I分别为 (2 6.9± 17.4) %、 (3 3 .1± 2 2 .7) %、 (73 .8± 16.3 ) % ,各级之间差异均有显著性(P均 <0 .0 5 ) ;Ki- 67L I分别为 (2 5 .8± 15 .6) %、 (5 8.2± 18.6) %、 (75 .3± 2 0 .2 ) % ,各级之间差异均有显著性 (P均 <0 .0 5 ) ;但各级 HCC中的 PCNA L I和 Ki- 67L I差异均无显著性 (P均 >0 .0 5 )。肝硬化组织中 PCNAL I为 (8.8± 5 .2 ) % ,Ki- 67L I为 (7.9± 4.4) % ,两者之间差异无显著性 (P>0 .0 5 )。提示 HCC及肝硬化组织中 PCNA和 Ki- 67抗原的阳性率基本一致 ,HCC的分化程度与 PCNA或 Ki- 67密切相关 ;原位检测 HCC组织中PCNA或 Ki- 67抗原的表达 ,有助于判断

拓扑异构酶Ⅱα和Ki-67表达与子宫肉瘤预后的相关性研究

目的通过检测DNA拓扑异构酶Ⅱα(TopoⅡα)、细胞核相关抗原-67(Ki-67)的表达水平,评价子宫肉瘤细胞增殖的生物学行为,寻找其预后相关因素。方法回顾性分析解放军总医院因子宫肉瘤行肿瘤切除手术的患者48例。按照国际妇产科联盟(FIGO)分期标准,分为Ⅰ期22例,Ⅱ期12例,Ⅲ期8例,Ⅳ期6例。按照美国妇科肿瘤组(GOG)病理组织学分类,包括子宫平滑肌肉瘤(LMS)19例,子宫内膜间质肉瘤(ESS)21例,子宫恶性中胚叶混合瘤(MMMT)8例。应用免疫组织化学(IHC)方法检测TopoⅡα、Ki-67在子宫肉瘤中的表达水平并分析其与子宫肉瘤预后的相关性。结果TopoⅡα和Ki-67的高增殖(LI)组(阳性表达细胞数>25%)患者的2年、5年生存率与低LI组(阳性表达细胞数≤25%)患者比较均无明显差别,但总体生存率高LI组均明显低于低LI组(分别为P=0.002,P=0.004)。TopoⅡα和ki-67低LI组患者的复发包块体积均大于高LI组(P=0.005,P=0.000),且复发时间均明显长于高LI组(P=0.000,P=0.000)。TopoⅡα与Ki-67表达呈明显正相关(r=0.9355,P=0.000)。COX多因素分析表明,除病理类型及分期外,TopoⅡα和Ki-67的表达与患病年龄、初潮年龄、孕产次、月经周期及经期、是否绝经均无关。结论TopoⅡα与Ki-67均可作为细胞增殖的特异性标记物,但TopoⅡα在反映细胞精确的增殖状态方面较Ki-67可能有更好的特异性,结合病理类型及分期,可能对判断子宫肉瘤的预后具有重要指导意义。

Ki-67在急性髓系白血病中的研究进展

Ki-67抗原表达与细胞周期密切相关,几乎表达于整个细胞周期的分裂期,检测Ki-67抗原可以反映血液肿瘤的细胞增殖活性。Ki-67的检测已广泛应用于淋巴瘤的疾病分期,疗效监测和预后判断,并已有大量研究探讨了Ki-67表达在急性淋巴细胞白血病(acute lymphocytic leukemia,ALL)和慢性淋巴细胞白血病(chronic lymphocytic leukemia,CLL)中的表达及与治疗疗效、预后的相关性,而在急性髓系白血病(acute myeloid leukemia,AM L)中Ki-67表达的相关研究较少,研究结果也不一致。本文就Ki-67的结构、细胞内定位、表达调控、生理功能及其在AM L中的应用现状做一综述,旨在了解Ki-67可否在AM L的诊断以及预后评估中发挥作用。